According to a new market report published by Lucintel, the future of the neurotrophic keratitis market looks promising with opportunities in stage I, stage II, and stage III applications. The global neurotrophic keratitis market is expected to grow with a CAGR of 5% from 2020 to 2025. The major drivers for this market are increase in special designation from the regulatory authorities, huge financial support to researchers for developing novel intervention, high demand for disease specific novel treatment, and recent launches of products.
To download report brochure, please go to https://www.lucintel.com/neurotrophic-keratitis-market.aspx and click "download brochure" tab from the menu
Neurotrophic keratitis (NK) is a degenerative disease characterized by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. In this market, drugs, devices, and surgery are the major treatments used for curing neurotrophic keratitis. Lucintel forecasts that drugs will remain the largest treatment segment over the forecast period due to increase in clinical studies, approvals, and launch of various novel products.
Within this market, stage I will remain the largest application segment over the forecast period due to high prevalence of early symptoms in stage I and high demand for preservative-free artificial tears.
North America will remain the largest region over the forecast period due to rise in product approvals, well-established health care infrastructure, increase in technological advancements, rise in number of well-equipped laboratories, surge in research & developmental activities in neurotrophic keratitis, growing healthcare industry, and presence of key players in the region.
Allergan, Bausch Health, and Bayer are among the major suppliers in the global neurotrophic keratitis market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global neurotrophic keratitis market by treatment, route of administration, end user, distribution channel, application, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Neurotrophic Keratitis Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global neurotrophic keratitis market by treatment, route of administration, end user, distribution channel, application, and region as follows:
By Treatment [Value ($ Million) shipment analysis for 2014 – 2025]:
By Route of Administration [Value ($ Million) shipment analysis for 2014 – 2025]:
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Homecare
Speciality Clinics
Others
By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Stage I
Stage II
Stage III
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Spain
Germany
France
This more than 150 page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.